Hotgen's invested company SGC001's innovative drug Phase Ib clinical trial has obtained positive preliminary results

Hotgen announced that its affiliated company ShunJing Pharmaceutical's innovative drug SGC001 has achieved positive preliminary results in Phase Ib clinical research. The study shows that in patients with anterior ST-segment elevation myocardial infarction receiving PCI treatment, SGC001 demonstrated an effective trend in myocardial protection in the 600mg and 900mg dosage groups compared to the placebo group, with a significant reduction in the percentage of myocardial infarction area (IS%) and a shorter time for high-sensitivity cardiac troponin I and high-sensitivity C-reactive protein to return to normal. The project will continue to advance according to the clinical trial protocol